

# **TOK-8801** Catalog No: tcsc0018158

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

**Specifications** 

#### CAS No:

105963-46-0

#### Formula:

 $\mathrm{C_{17}H_{21}N_{3}OS}$ 

#### Pathway:

Others

### **Target:**

Others

**Purity / Grade:** 

## **Solubility:** 10 mM in DMSO

### **Observed Molecular Weight:**

315.43

# **Product Description**

TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator.


In Vitro: TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator. TOK-

Copyright 2021 Taiclone Biotech Corp.



8801 augments the *in vitro* anti-SRBC PFC response of murine splenocytes in a bell-shaped manner. The stimulatory effect of TOK-8801 is observed at concentrations of  $2.5 \times 10^{-7}$  to  $2.5 \times 10^{-5}$  M and is diminished at  $10^{-4}$  M. The cell-viability is not altered during the culture with TOK-8801 at any doses used in this experiment ( $10^{-7}$  to  $10^{-4}$  M). TOK-8801 enhances the <sup>3</sup>H-TdR uptake of these responses in a bell-shaped manner, and effective concentrations of TOK-8801 are  $10^{-7}$  to  $10^{-5}$  M<sup>[1]</sup>.

*In Vivo:* The anti-SRBC PFC response per spleen, which is prominently lowered by restraint-stress (P[1]. When TOK-8801 is administered orally at doses of 0.1 to 10 mg/kg, the number of plaque forming cell (PFC) significantly decreases or tends to decrease. Treatment of TOK-8801 at doses of 0.1 to 1 mg/kg causes significant suppression in the delayed-type hypersensitivity (DTH) reaction induced in high responder<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.